BY PEOPLE. WITH PEOPLE. FOR PEOPLE.

Transcription

1 BY PEOPLE. WITH PEOPLE. FOR PEOPLE. :: 4SC AG, ENNO SPILLNER KORRELATION UNTERNEHMENSNACHRICHTEN & UNTERNEHMENSBEWERTUNG BERLIN, 19. MÄRZ 2013

2 FORWARD LOOKING STATEMENTS This presentation may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors. 2

3 4SC AT A GLANCE MISSION BUSINESS FOCUS FINANCE & SHARES ATTRACTIVE GOALS AHEAD 4SC discovers and develops targeted small-molecule therapies against cancer & inflammation towards approval and/or commercialisation Integrated drug discovery and development platform Broad & balanced product pipeline in Phase I and II Growth through pharma partnerships Committed investor base Market cap. 92m (18 March 2013) Prime Standard listing (@ Deutsche Börse) Capital increase with gross proceeds of 12.6m successfully completed in July 2012 Preparing late-stage studies in blockbuster indications Resminostat: Pivotal Phase III study in liver cancer (HCC) in preparation (pharma deal next key milestone) Vidofludimus: Phase IIb study in IBD in preparation 3

4 A BROAD AND VALUE-FOCUSED PIPELINE 4

5 4SC CORPORATE STRUCTURE 4SC GROUP OWNS

6 4SC DISCOVERY GMBH GENERATING REVENUE FROM RESEARCH COLLABORATION & EARLY-STAGE DEALS 4SC Discovery GmbH - Commercialisation of Early-Stage Research Fully owned subsidiary of 4SC AG, 26 skilled scientists Covering entire value chain in drug discovery (in silico screening, medicinal chemistry, PK analysis etc.) Scope of Partnerships Small molecule discovery services & collaborations Licensing partnerships with early-stage drug candidates Successful Start Milestone payment from SKK (March 2012) Research collaboration with Henkel (April 2012) Marketing partnership with Crelux (April 2012) Research collaboration with Ribological (June 2012) 0.6 m research grant for cancer immunotherapy (Oct. 2012) Exclusive license agreement with BioNTech in cancer immunotherapy with 2.5 m upfront payment (Dec 2012) 3-year research collaboration with BioNTech (Feb. 2013) Exclusive license agreement with LEO Pharma in psoriasis with 1m upfront payment (Feb. 2013) 6

7 SHAREHOLDERS STRUCTURE* Number of shares outstanding: 50,371,814 Free Float acc. to Deutsche Börse: 30.0% Share liquidity constantly increased Capital increase (June/July 2012): 8,403,510 new shares placed at price of 1,50 per share; gross proceeds of 12.6 m Strong backing by family office and experienced life science investors Ø No of shares traded per day Xetra All ** ,050 14, ,307 43, ,434 56,713 Analyst ** All German exchanges plus Tradegate Price target Edison 3.80 Equinet 3.60 Kempen 3.00 MM Warburg 3.55 * Based on management estimates. 7

8 4SC: YTD SELECTED MILESTONES & EVENTS 8

9 STOCK MARKETS DEVELOPMENT (2011, 2012, 2013 YTD) FUKUSHIMA EURO CRISIS: ESM EURO CRISIS: GREEK ELECTION Nasdaq Biotech DOW Jones DAX TecDAX DAXsubsector Biotechnology 9

10 4SC VS BENCHMARK INDICES (2011, 2012, 2013 YTD) Nasdaq Biotech DAXsubsector Biotechnology TecDAX DAX 4SC AG 10

11 4SC VS BENCHMARK INDICES (2011) FUKUSHIMA YAKULT DEAL EURO CRISIS: ESM??? CAP. INC. 10% PORTFOLIO ADJUSTMENTS RA PHASE II DATA Nasdaq Biotech DAXsubsector Biotechnology TecDAX DAX 4SC AG 11

12 4SC VS BENCHMARK INDICES (2012, 2013 YTD) PH. II TOPLINE DATA HCC PH. II PFS DATA HCC PH. II OS DATA HCC - PATENT RESM. (OKT) - PH I DATA (205, RESM.) (DEC) - BIONTECH DEAL (DEC) - LEO DEAL, - BIONTECH 3- YEAR COLLAB. CAPITAL INCREASE LOSS 92 AKTG Nasdaq Biotech DAXsubsector Biotechnology TecDAX DAX 4SC AG 12

13 CONCLUSIONS 4SC share, largely, follows overall market trends Some exceptions to the rule 4SC share price reacts significantly on news releases Strength of reaction varies with relevance of news flow Relevance can be measured by market proximity & market potential Bad news with stronger impact than good news Clinical efficacy data: very strong reaction Strength of reaction varies with market proximity (Ph. II vs. Ph. I) and indication (HCC vs. HL) Capital increase: reaction following discount Full-blown cap. inc. (considerable discount) vs. 10% cap. inc. (marginal discount) Patent & orphan drug news: sizable reaction Strength of reaction varies with market proximity (Ph. II vs. Ph. I) and indication (HCC vs. HL) 4SC Discovery: generally relatively small reaction (low market proximity!) Financial reporting news: no share price reaction No big surprises due to good guidance ; lower relevance compared to clinical data Share liquidity as a challenge and potential catalyst GENERAL RULE: THE MORE EARLY-STAGE, THE LESS IMPACT OR: THE CLOSER TO THE MARKET, THE MORE IMPACT 13

14 :: BY PEOPLE. WITH PEOPLE. FOR PEOPLE THANK YOU VERY MUCH! :: CONTACT Enno Spillner, CFO 14